1K9 Stock Chart & Stats
€32.60
€0.00(0.00%)
At close: 4:00 PM EDT
€32.60
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€9.83 - €41.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.96B
Enterprise Value€1.17K
Total Cash (Recent Filing)€373.64M
Total Debt (Recent Filing)€19.25M
Price to Earnings (P/E)20.3
Beta0.30
Next Earnings
Nov 10, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.15
Shares Outstanding51,734,222
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.31
Price to Sales (P/S)2.64
P/FCF Ratio27.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€41.32Price Target Upside26.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)1.05
Revenue Forecast (FY)€423.70M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetCareDx's modest leverage and materially stronger equity position provide durable financial flexibility. Low debt reduces refinancing and covenant risk, enabling funding for strategic M&A, buybacks, or clinical investments over the next 2–6 months without forcing dilutive financing if results vary.
Improved Cash Generation And MarginsSustainably positive free cash flow and strong gross margins support reinvestment and margin resilience as testing scales. Close free‑cash‑flow to net income signals earnings quality, meaning the company can self-fund growth, pay down liabilities, or return capital without relying on external markets.
Portfolio Refocus And Navaris AcquisitionSelling lower-margin lab products and buying Navaris reallocates capital to higher-growth, better‑reimbursed precision testing markets. Navaris' Medicare/ADLT coverage and clinical publications expand addressable markets and long‑term revenue durability if integration and scaling succeed.
Bears Say
Reimbursement/LCD UncertaintyPotential MolDX LCD decisions create structural reimbursement risk for test coverage and pricing. A sustained adverse LCD or reimbursement reset could reduce per-test revenue and slow adoption, pressuring margins and cash flow over the coming quarters until coverage clarity is established.
Revenue Recognition And Timing NoiseMaterial out‑of‑period revenue and receipt timing can obscure underlying demand and per‑test economics. Persistent timing variability raises forecasting risk, complicates trend analysis for reimbursements and collections, and can make near‑term performance appear less reliable to stakeholders.
Integration And Scale Risks For NavarisRealizing Navaris' projected 30–40%+ growth and margin uplift requires operational scale and automation. Execution risk—automation, cost reductions, clinical validation timelines—could delay synergies, keep unit costs elevated, and pressure near-term adjusted EBITDA despite strategic benefits.
CareDx News
1K9 FAQ
What was CareDx Inc’s price range in the past 12 months?
CareDx Inc lowest stock price was €9.83 and its highest was €41.20 in the past 12 months.
What is CareDx Inc’s market cap?
CareDx Inc’s market cap is €1.96B.
When is CareDx Inc’s upcoming earnings report date?
CareDx Inc’s upcoming earnings report date is Nov 10, 2026 which is in 94 days.
How were CareDx Inc’s earnings last quarter?
CareDx Inc released its earnings results on Jul 30, 2026. The company reported €0.32 earnings per share for the quarter, beating the consensus estimate of €0.201 by €0.119.
Is CareDx Inc overvalued?
According to Wall Street analysts CareDx Inc’s price is currently Undervalued.
Does CareDx Inc pay dividends?
CareDx Inc does not currently pay dividends.
What is CareDx Inc’s EPS estimate?
CareDx Inc’s EPS estimate is 0.22.
How many shares outstanding does CareDx Inc have?
CareDx Inc has 51,734,222 shares outstanding.
What happened to CareDx Inc’s price movement after its last earnings report?
CareDx Inc reported an EPS of €0.32 in its last earnings report, beating expectations of €0.201. Following the earnings report the stock price went up 16.993%.
Which hedge fund is a major shareholder of CareDx Inc?
Currently, no hedge funds are holding shares in DE:1K9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareDx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€41.32 (26.74% Upside)
€41.32 (26.74% Upside)
Blogger Sentiment
Bearish
DE:1K9 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €3.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
184.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.97%
Trailing 12-Months
Company Description
CareDx Inc
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
1K9 Company Deck
1K9 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong top-line growth, substantial margin and EBITDA improvement, raised full‑year guidance, a strategic simplification via a Lab Products divestiture (expected ~$160M net proceeds), and a targeted acquisition (Navaris) that expands addressable markets with strong clinical evidence and favorable reimbursement. Challenges include modest profitability and declining trends in the Lab Products segment prior to divestiture, revenue recognition timing noise, reimbursement/LCD risk (~$7.5M modeled headwind), elevated operating expenses and uncertainty in transplant procedure volumes, and integration/scale risks for Navaris and the product carve-out. On balance, the positive growth, improved profitability, cash position, and strategic actions outweigh the execution and timing risks discussed on the call.View all DE:1K9 earnings summaries1K9 Stock 12 Month Forecast
Average Price Target
€41.32
▲(26.74% Upside)